Helicobacter-Therapie[1]

Literatur

• 1 Bayerdörffer E, Hansky K, Schneider-Brachert W, Kirsch C, Kroettinger A, Bästlein E, Haferland C, Buchner M, Heptner G, Stolte M, Jacobs E, Miehlke S, Lehn N. Treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin - a prospective randomized trial comparing a 7-day rifabutin-based triple therapy with a high-dose omeprazole/amoxicillin dual therapy.  GUT. 2002;  51 (suppl II) A91
• 2 Bayerdörffer E, Kasper G, Pirlet T, Sommer A, Ottenjann R. Ofloxacin in der Therapie Campylobacter-pylori-positiver Ulcera duodeni.  Dtsch Med Wochenschr. 1987;  112 1407-1411
• 3 Bayerdörffer E, Lonovics J, Dite P, Diete U, Domjan L, Kisfalvi I, Megraud F, Pap A, Sipponen P, Burman C F, Zeijlon L. Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.  Aliment Pharmacol Ther. 1999;  13 1599-1605
• 4 Bayerdörffer E, Miehlke S, Mannes G A, Sommer A, Höchter W, Heldwein W, Weingart J, Klann H, Simon T, Schmitt W, Bästlein E, Eimiller A, Hatz R, Lehn N, Dirschedl P, Stolte M. Double blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.  Gastroenterology. 1995;  108 1412-1417
• 5 Cammarota G, Cianci R, Cannizzaro-Ocuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco M A, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.  Aliment Pharmacol Ther. 2000;  14 1339-1343
• 6 Caspary W F, Arnold R, Bayerdörffer E, Behrens R, Birkner B, Braden B, Domschke W, Labenz J, Koletzko S, Malfertheiner P, Menge H, Rösch W, Schepp W, Strauch W, Stolte M. Diagnostik und Therapie der Helicobacter pylori Infektion. Leitlinien der DGVS.  Z Gastroenterol. 1996;  34 392-401
• 7 DeBoer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.  Lancet. 1995;  345 817-820
• 8 Dixon M F, Genta R M, Yardley J H, Correa P. et al . Classification and grading of gastritis. The updated Sydney-System.  Am J Surg Pathol. 1996;  20 1161-1181
• 9 Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.  Eur J Clin Microbiol Infect Dis. 2000;  19 538-541
• 10 van der Hulst R W, van der Ende A, Homan A, Roorda P, Dankert J, Tytgat G N. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication.  Gut. 1998;  42 166-169
• 11 Jaup B. Dual „rescue” therapy for eradication of H. pylori in previous triple therapy failure.  Gut. 1999;  45 A118
• 12 Lind T, Mégraud F, Unge P, Bayerdörffer E, O’Morain C, Spiller R, Veldhuyzen van Zanten S, Bardhan K D, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C. The MACH2-Study - The role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies.  Gastroenterology. 1999;  116 248-253
• 13 Lind T, Veldhuyzen van Zanten S JO, Unge P, Spiller R C, Bayerdörffer E, O’Morain C, Wrangstadh M, Idström J P. The MACH 1 study: Optimal one-week treatment for H. pylori defined?.  Helicobacter. 1996;  1 138-144
• 14 Madisch A, Bayerdörffer E, Bästlein E, Schneider-Brachert W, Hänel C, Piehler P, Haferland C, Buchner M, Meier E, Trump F, Antos D, Schimming W, Breidert M, Stolte M, Lehn N, Miehlke S. 7-day triple therapy with esomeprazole, levofloxacin and amoxycillin is effective in patients with metronidazole- and clarithromycin-sensitive and -resistant H. pylori strains.  Gastroenterology. 2003;  124 (suppl 1) A102
• 15 Miehlke S, Kirsch C, Schneider-Brachert W, Bästlein E, Haferland C, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdörffer E. Effective one-week triple therapy with esomeprazole, clarithromycin and metronidazole for eradication of Helicobacter pylori in the absence of antimicrobial resistance: A prospective randomized trial.  Aliment Pharmacol Ther. 2003;  18 799-804
• 16 Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bästlein E, Vieth M, Lehn N, Stolte M, Bayerdörffer E. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant against both metronidazole and clarithromycin.  Helicobacter. 2003;  8 310-319
• 17 Malfertheiner P, Megraud F, O’Morain C, Hungin A PS, Jones R, Axon A, Graham D Y, Tytgat G NT. The European Helicobactger pylori Study Group (EHPSG) . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 consensus report.  Aliment Pharmacol Ther. 2002;  16 167-180
• 18 Perri F, Festa V, Clemente R, Villani M R, Quitadamo M, Caruso N, Bergoli M L, Andrulli A. Randomized study of two „rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.  Am J Gastroenterol. 2001;  96 58-62
• 19 van Zanten S, Lauritsen K, Delchier J -C, Labenz J, de Agrila C M, Lind T, Treichel H -C, Stubberöd A, Cockeram A, Hasselgren G, Göthe L, Wrangstadh M, Sinclair P. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.  Aliment Pharmacol Ther. 2000;  14 1605-1611

1 Mit Berichten von der Jahrestagung der Amerikanischen Gastroenterologischen Gesellschaft (AGA) im Mai 2003 in Orlando sowie den Herbsttagungen der European Helicobacter pylori Study Group, Athen 11-14 Sep, 2002 (EHPSG), von der United European Gastroenterology Week, Genf 19 - 23 Okt, 2002 (UEGW) und der Helicobacter-Tagung ’Basic Mechanisms to Clinical Cure’ 10 -13 Nov 2002 auf Maui/Hawaii